Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Sunitinib | Sunitinib (as the malate salt) is the active ingredient in the drug sold under the trade name Sutent. This drug is a small molecule receptor tyrosine kinase inhibitor that has been approved in at least one country for the treatment of patients having gastrointestinal stromal tumors or renal cell carcinomas. Group: Biochemicals. Alternative Names: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU-11248; Sutent; PHA-290940AD; PNU-290940AD. Grades: Highly Purified. CAS No. 557795-19-4. Pack Sizes: 10mg, 100mg. Molecular Formula: C22H27FN4O2, Molecular Weight: 398.47. US Biological Life Sciences. |  Worldwide |
| Sunitinib | Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC 50 s of 80 nM and 2 nM for VEGFR2 and PDGFRβ , respectively [1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SU 11248. CAS No. 557795-19-4. Pack Sizes: 10 mM * 1 mL; 100 mg; 200 mg; 500 mg. Product ID: HY-10255A. |  |
| Sunitinib-d10 | Labeled Sunitinib, a multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Group: Biochemicals. Grades: Highly Purified. CAS No. 1126721-82-1. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| Sunitinib-[d10] | One of the isotopic labelled form of Sunitinib, which is a receptor tyrosine kinases inhibitor. Synonyms: N-[2-(Diethyl-d10)aminoethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sutent-d10; SU-11248-d10. Grade: >95%. CAS No. 1126721-82-1. Molecular formula: C22H17D10FN4O2. Mole weight: 408.47. |  |
| Sunitinib Impurity 6 | Sunitinib Impurity 6. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1691223-83-2. Molecular formula: C22H27FN4O2. Mole weight: 398.48. Catalog: APB1691223832. |  |
| Sunitinib Impurity 61 | Sunitinib Impurity 61. Uses: For analytical and research use. Group: Impurity standards. CAS No. 100487-78-3. Molecular formula: C8H6ClN3O. Mole weight: 195.61. Catalog: APB100487783. | |
| Sunitinib malate | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| Sunitinib malate | Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Uses: Angiogenesis inhibitors. Synonyms: Sunitinib malate; SU011248 L-malate salt; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid. Grade: >98%. CAS No. 341031-54-7. Molecular formula: C22H27FN4O2.C4H6O5. Mole weight: 532.56. | |
| Sunitinib Malate | A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic. Group: Biochemicals. Alternative Names: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Malate; Sutent; SU-11248. Grades: Highly Purified. CAS No. 341031-54-7. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| Sunitinib Malate | Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC 50 s of 80 nM and 2 nM for VEGFR2 and PDGFRβ , respectively [1]. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SU 11248 Malate. CAS No. 341031-54-7. Pack Sizes: 10 mM * 1 mL; 100 mg; 200 mg; 500 mg. Product ID: HY-10255. | |
| Sunitinib Maleate (Sutent, Sunitinib Malate, SU-11248, PHA-290940AD, PNU-290940AD) | A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases, including platelet-derived growth factor receptor and vascular endothelial growth factor receptor, that are associated with tumor growth and angiogenesis. Group: Biochemicals. Alternative Names: Sutent. Grades: Highly Purified. CAS No. 341031-54-7. Pack Sizes: 100mg, 250mg, 500mg. US Biological Life Sciences. | Worldwide |
| Sunitinib N-Oxide | Sunitinib N-Oxide. Group: Biochemicals. Alternative Names: N-[2- (Diethyloxidoamino) ethyl]-5-[ (Z) - (5-fluoro-1, 2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)amide. Grades: Highly Purified. CAS No. 356068-99-0. Pack Sizes: 10mg. Molecular Formula: C22H27FN4O3, Molecular Weight: 414.47. US Biological Life Sciences. | Worldwide |
| Sunitinib N-Oxide-d10 | Sunitinib N-Oxide-d10. Group: Biochemicals. Alternative Names: N-[2- (Diethyloxidoamino) ethyl]-5-[ (Z) - (5-fluoro-1, 2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide-d10; 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)amide-d10. Grades: Highly Purified. Pack Sizes: 500ug. Molecular Formula: C22H17D10FN4O3, Molecular Weight: 424.53. US Biological Life Sciences. | Worldwide |
| (E/Z)-N-Desethylsunitinib hydrochloride | (E/Z)-N-Desethylsunitinib hydrochloride ((E/Z)-SU-12662 hydrochloride) is a compound with potential anti-tumor activity that inhibits VEGF-R2 and PDGF-Rβ tyrosine kinases. (E/Z)-N-Desethylsunitinib hydrochloride is the main active metabolite of sunitinib and has the ability to competitively inhibit ATP [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: (E/Z)-SU-12662 hydrochloride. CAS No. 1261432-05-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-138813A. | |
| N-Boc-N,N-didesethyl sunitinib | N-Boc-N,N-didesethyl sunitinib. Group: Biochemicals. Alternative Names: N-(N'-Boc-2-aminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide hydrochloride. Grades: Highly Purified. CAS No. 1227960-76-0. Pack Sizes: 1mg, 2mg, 5mg, 10mg. Molecular Formula: C23H27FN4O4. US Biological Life Sciences. | Worldwide |
| N-Desethyl Sunitinib | A metabolite of Sunitinib. Group: Biochemicals. Alternative Names: N-[2-(Ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Grades: Highly Purified. CAS No. 356068-97-8. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| N-Desethyl Sunitinib-d5 | A labeled metabolite of Sunitinib. Group: Biochemicals. Alternative Names: N-[2-(Ethylamino-d5)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| N,N-Didesethyl sunitinib hydrochloride | N,N-Didesethyl sunitinib hydrochloride. Uses: Designed for use in research and industrial production. Additional or Alternative Names: N-(2-Aminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Hydrochloride;N,N-Didesethyl Sunitinib Hydrochloride. Product Category: Heterocyclic Organic Compound. Appearance: Yellow Solid. CAS No. 873077-70-4. Molecular formula: C18H20ClFN4O2. Product ID: ACM873077704. Alfa Chemistry ISO 9001:2015 Certified. |  |
| N,N-Didesethyl Sunitinib Hydrochloride | A metabolite of Sunitinib. Group: Biochemicals. Alternative Names: N-(2-Aminoethyl)-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Hydrochloride. Grades: Highly Purified. CAS No. 1217216-61-9. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| N,N-Dimethyl sunitinib | N,N-Dimethyl sunitinib. Group: Biochemicals. Alternative Names: N-[2-(Dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide. Grades: Highly Purified. CAS No. 326914-17-4. Pack Sizes: 1mg, 2mg, 5mg, 10mg. Molecular Formula: C20H23FN4O2. US Biological Life Sciences. | Worldwide |
| 2-[2-(Diethylamino)ethyl]-1H-isoindole-1,3(2H)-dione | 2-[2-(Diethylamino)ethyl]-1H-isoindole-1,3(2H)-dione is an intermediate in synthesizing Sunitinib-d4 (S820003), a labelled Sunitinib (S820000), a multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg, 2.5mg. Molecular Formula: C14H14D4N2O2, Molecular Weight: 250.33. US Biological Life Sciences. | Worldwide |
| 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid | 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid is an intermediate of. Sunitinib, which is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Uses: Sunitinib intermediate. Synonyms: 5-[(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid; 1H-Pyrrole-3-carboxylic acid, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-. Grade: ≥95%. CAS No. 452105-33-8. Molecular formula: C16H13FN2O3. Mole weight: 300.29. | |
| 5-Fluoro-2-oxindole | 5-Fluoro-2-oxindole is an impurity of Sunitinib, which is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Synonyms: 2H-Indol-2-one, 5-fluoro-1,3-dihydro-; 5-Fluoro-1,3-dihydro-2H-indol-2-one; 5-Fluoro-2,3-dihydro-2-oxoindole; 5-Fluoro-2,3-dihydroindol-2-one; 5-Fluoro-2-oxoindoline; 5-Fluoroindolin-2-one; 5-Fluorooxindole. Grade: ≥95%. CAS No. 56341-41-4. Molecular formula: C8H6FNO. Mole weight: 151.14. | |
| 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid | 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid is an impurity of Sunitinib, which is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Synonyms: 1H-Pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl-; 2,4-Dimethyl-5-formyl-1H-pyrrole-3-carboxylic acid; 2,4-Dimethyl-5-formylpyrrole-3-carboxylic acid; 5-Formyl-2,4-dimethylpyrrole-3-carboxylic acid. Grade: ≥95%. CAS No. 253870-02-9. Molecular formula: C8H9NO3. Mole weight: 167.16. | |
| Angiogenesis related Compound Library | A unique collection of 1370 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS); - Targets include angiogenesis signaling, and related targets such as S1P, VEGFR, PDGF, etc. ; - Includes approved drugs targeting angiogenesis, such as Sunitinib Malate, Lenalidomide, sorafenib, Erlotinib; drugs in clinical development with the most potential targeting angiogenesis, such as Vatalanib, Orantinib, 2-Methoxyestradiol (Panzem), Celecoxib; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality. Uses: Scientific use. Product Category: L4800. Categories: Angiogenesis related Compounds Libraries. |  |
| DCC-2618 | DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. Synonyms: DCC2618; DCC 2618; c-Kit-IN-1; PDGFR inhibitor 1; N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide. Grade: >98%. CAS No. 1225278-16-9. Molecular formula: C26H21F2N5O3. Mole weight: 489.47. | |
| Dihydroberberine | Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene ( hERG ) channel and significantly reduces the expression of heat shock protein 90 ( Hsp90 ) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy [1] [2]. Uses: Scientific research. Group: Natural products. CAS No. 483-15-8. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-N1934. | |
| Ethyl 2,4-Dimethylpyrrole-3-carboxylate | Ethyl 2,4-Dimethylpyrrole-3-carboxylate is an impurity of Sunitinib, which is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Synonyms: 1H-Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester; 2,4-Dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester; 2,4-Dimethylpyrrole-3-carboxylic Acid Ethyl Ester; 2,4-Dimethyl-3-(ethoxycarbonyl)pyrrole; 2,4-Dimethyl-3-carbethoxypyrrole; 3-(Ethoxycarbonyl)-2,4-dimethylpyrrole; NSC 13425; Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester. Grade: ≥95%. CAS No. 2199-51-1. Molecular formula: C9H13NO2. Mole weight: 167.21. | |
| Ethyl 5-Formyl-2,4-dimethylpyrrole-3-carboxylate | Ethyl 5-Formyl-2,4-dimethylpyrrole-3-carboxylate is an impurity of Sunitinib, which is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Synonyms: 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester; Ethyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylate; 2,4-Dimethyl-3-ethoxycarbonyl-5-formylpyrrole; 4-Ethoxycarbonyl-3,5-dimethylpyrrole-2-carboxaldehyde; 5-Formyl-2,4-dimethylpyrrole-3-carboxylic Acid Ethyl Ester; Ethyl 2,4-Dimethyl-5-formylpyrrole-3-carboxylate; Ethyl 2-Formyl-3,5-dimethylpyrrole-4-carboxylate; NSC 13426; 1H-Pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl-, ethyl ester; Pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl-, ethyl ester. Grade: ≥95%. CAS No. 2199-59-9. Molecular formula: C10H13NO3. Mole weight: 195.22. | |
| Famitinib | Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer treatment. Famitinib is a structural analogue ofsunitinib, is a novel and potent multi-targeted RTK inhibitor that is currently undergoing phase II clinical trials in China for the treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma. Compared with sunitinib, famitinib exhibits superior inhibition activities against multiple RTKs. Synonyms: 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one; SHR1020; SHR 1020; SHR-1020; 4H-Pyrrolo[3,2-c]pyridin-4-one, 5-[2-(diethylamino)ethyl]-2-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1,5,6,7-tetrahydro-3-methyl-. Grade: ≥98%. CAS No. 945380-27-8. Molecular formula: C23H27FN4O2. Mole weight: 410.48. | |
| Henatinib | Henatinib inhibits vascular endothelial growth factor receptor type 2 (VEGFR2), a tyrosine kinase receptor upregulated in many tumor cells that plays a key role in angiogenesis. This may result in an inhibition of angiogenesis and eventually tumor cell proliferation. Henatinib, structurally similar to sunitinib, also inhibits, though to a lesser extent, mast/stem cell growth factor receptor (c-Kit) and, platelet-derived growth factor receptor (PDGFR) alpha and beta. Synonyms: (R,Z)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azepin-4-one. CAS No. 1239269-51-2. Molecular formula: C25H29FN4O4. Mole weight: 468.53. | |
| N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide | Sunitinib (as the malate salt) is the active ingredient in the drug sold under the trade name Sutent. This drug is a small molecule receptor tyrosine kinase inhibitor that has been approved in at least one country for the treatment of patients having gastrointestinal stromal tumors or renal cell carcinomas. Group: Biochemicals. Alternative Names: N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU-11248; Sutent; PHA-290940AD; PNU-290940AD. Grades: Highly Purified. CAS No. 557795-19-4. Pack Sizes: 500mg, 1g, 2g, 5g, 10g. Molecular Formula: C22H27FN4O2, Molecular Weight: 398.47. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
